Clinical Trial Update: A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase II/III study evaluating HLX87 in combination with HLX22 or Pertuzumab as neoadjuvant therapy for HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HLX22
• HLX87 (HLX87)
• Pertuzumab (pertuzumab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: HER2 + Breast Cancer | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING